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A New Outlook in Lymphatic 
Filariasis Elimination in India
Susanta Kumar Ghosh and Pradeep Kumar Srivastava
Abstract
In India, human lymphatic filariasis (LF) is the most common vector-borne 
disease after malaria. It is a roundworm nematode parasitic helminthiases group 
of diseases under Filarioidea type of infection. The parasites are found in the 
lymphatic system, damage the system leading to deformities of body organs. Of the 
eight human filarial parasites, Wuchereria bancrofti, Brugia malayi and B. timori 
are involved with the lymphatic system. Globally W. bancrofti is the most pre-
dominant species sharing 90% of the burden. In India, W. bancrofti and B. malayi 
are present. The revised control strategy was aimed at a single-dose mass drug 
administration (MDA) and home-based morbidity management. The Elimination 
of LF (ELF) was initiated in 2004 in 202 districts which were expanded later in 
256 districts after a pilot study in LF endemic districts initiated in 1997. The initial 
start of ELF campaign was with a single drug, i.e. diethylcarbamazine (DEC), but 
later in 2007, a combination of two drugs DEC and albendazole (ALB) were given 
through MDA. Now a third drug ivermectin (IVM) has been added to accelerate the 
elimination process by 2020 which is the global goal of elimination under Global 
Programme to Eliminate Lymphatic Filariasis (GPELF).
Keywords: lymphatic filariasis, elimination, Wuchereria bancrofti, Brugia malayi, 
diethylcarbamazine, albendazole, ivermectin, DEC-medicated salt, transmission 
assessment survey, xenomonitoring
1. Introduction
There are eight parasites responsible for filarial infections. Three parasites 
Wuchereria bancrofti (Cobbold 1877), Brugia malayi (Brug 1927) and B. timori 
(Partono et al. 1977) are responsible for lymphatic filariasis (LF) that impairs the 
lymphatic system leading to severe organ deformities leading to social stigma [1–3]. 
In India, the first two species W. bancrofti and B. malayi are present. W. bancrofti 
contributes 99.4% of the total burden. It is a roundworm nematode parasitic 
helminthiasis group of diseases under the Filarioidea type of infection. The main 
affected organs are legs and genitals causing ‘elephantiasis’ and hydrocele in males 
and breast filariasis in females followed by relentless disability causing social 
stigma. In Indian local language the disease is known as ‘Hathipaon’. In India, LF is 
the second most vector-borne disease after malaria and globally ranks third after 
malaria and tuberculosis. The World Health Organization (WHO) estimated that 
LF is found in 81 tropical and subtropical countries with 120 million infected cases 
and with one billion people at risk; 947 million people are threatened, whereas 40 
million people are disfigured by this infection. Four countries India, Indonesia, 
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Bangladesh (all Asian countries) and Nigeria (Africa) contribute about 70% of the 
LF infection in the world [4].
In the sixth century BC in his book, Susruta Samhita, Susruta mentioned 
this disease. In the seventh century AD in his memoir, Madhava Nidhana, 
Madhavarakara first described the signs and symptoms of this disease. In 1709, 
Clarke described ‘Malabar legs’ from Cochin which is synonymous with elephantia-
sis. In 1872 in Calcutta (now Kolkata), Lewis first described the microfilariae (Mf) 
in human blood [5].
LF is distributed in economically challenged countries. W. bancrofti is the most 
predominant species of human filariasis. It was recognized primarily as an urban 
disease which does not have animal reservoirs. Later it is reported from rural areas 
also. The parasites develop only in humans and in mosquitoes. But the adult worms 
may survive for 8–10 years and produce huge numbers of Mf from time to time. 
This is actually the real challenge in containing the disease.
2. Search methods
We have searched MEDLINE (PubMed) and CAB Abstracts, checked the 
reference lists of all studies identified by the search, also performed Google Search 
on specific topics and examined references listed in review articles and previously 
compiled bibliographies.
3. Genesis and evolution of the elimination of lymphatic filariasis
LF is responsible for deformities and disfigures of potential organs caused by this 
disease which make social stigma leading to hardship on normal life. Many mar-
riageable persons undergo physical and psychological distress throughout their lives. 
LF is one of the six infectious diseases identified by the International Task Force for 
Disease Eradication of the WHO as ‘eradicable’ or ‘potentially eradicable’ in 1993 
[6]. In 1997, the World Health Assembly resolved to eliminate LF as a public health 
problem globally [7]. In 2000, the WHO launched Global Programme to Eliminate 
Lymphatic Filariasis (GPELF). Following the London declaration on neglected 
tropical diseases (NTDs) in 2012, and consequent on several recent advances on the 
new knowledge of the pathogenesis, the biology of the parasite, development of 
better diagnostic tools and treatment strategies of LF, GPELF has an aim to elimi-
nate this disease globally by 2020. India, a signatory to the World Health Assembly 
resolution, had initially set the target for elimination of filariasis by the year 2015 [4] 
but later aligned with global target of 2020 which is again to be reset. This pro-
gramme is based on two components consisting of (i) interruption of transmission 
to prevent the disease by mass drug administration (MDA) and (ii) alleviation of the 
morbidity (lymphedema and hydrocele) associated with the disease [8]. Of the two 
strategies, preventive chemotherapy delivered through MDA has gained prominence 
as interruption of transmission after the implementation of the GPELF.
4. Mass drug administration: scientific background
Before the concept of MDA, the main strategy of LF management was selective 
treatment by identifying Mf carriers microscopically and/or clinically manifested 
cases and their treatment with diethylcarbamazine (DEC) for 12 days for indi-
vidual cure. This strategy was focused on individual level where the people with 
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low parasitaemia and asymptomatic were left and therefore infection persisted in 
the community. In the subsequent years, there were significant improvements of 
LF diagnosis and treatment. Combination of double to triple drugs in single doses 
has been found to be efficacious than monotherapy. Albendazole (ALB) and more 
recent ivermectin (IVM) have been added to DEC. Now DEC + ALB is used in the 
MDA programme, and additionally IVM has been advocated for treating the entire 
population at high risk [5].
Human pharmacokinetic studies on the two regimens of single-dose drugs 
have shown that all the three drugs when administered singly or as a partner 
were well tolerated and safe in both microfilaraemic and non-microfilaraemic 
cases. Efficacy studies of repeated annual MDAs on different combination drugs 
of ALB + DEC, ALB + IVM and DEC + IVM indicated significant reductions on 
Mf rate for long periods [9]. Microsimulation models based on drug coverage, 
its efficacy and endemicity level of LF have indicated the effectiveness of MDA 
on ELF. This enabled to assess the number of MDA rounds necessary to achieve 
elimination [10, 11].
5. Filariasis control initiatives in India
LF is considered one of the NTDs that cause huge deformities and disabilities 
on the society. India contributes the major burden globally. The initial effort was 
to establish the concept of controlling the disease. In the concept of its elimination 
on the line of global initiative, India has made significant progress. In India, LF is 
caused by two roundworm nematode parasites W. bancrofti and B. malayi and is 
transmitted by the mosquito vectors Culex quinquefasciatus, Mansonia annulifera 
and M. uniformis. B. malayi which contributes to a negligible proportion is present 
in Kerala, Andhra Pradesh, Odisha, Madhya Pradesh, Assam and West Bengal. In 
general, Bihar state has the highest endemicity while Goa the lowest [12]. Here a 
detailed recent account has been enumerated.
5.1 National filaria control programme
After the pilot project in Orissa from 1949 to 1954 and based on its assessment, 
In India, the National Filaria Control Programme (NFCP) was launched in 1955. 
The main objective was to control the problem, have effective planning for control 
measures in endemic areas and also to train health personnel to strengthen the pro-
gramme. The immediate control measures were mass drug administration of DEC, 
antilarval measures in urban areas and indoor residual spray in the rural areas. The 
programme was assessed four times by the assessment committees in 1961, 1971, 
1982 and 1995, respectively. In 1961, the assessment revealed the failure of mass 
DEC administration due to community reluctance and ineffectiveness of insec-
ticidal indoor spray due to the high resistance in the vector, and therefore as per 
recommendation of assessment committee, recurrent antilarval measures, estab-
lishment of new control units in endemic urban areas and provision of disposal 
of sewage and sullage were instituted. In 1971, the assessment committee recom-
mended the detection and treatment of Mf cases with DEC at a dose of 6 mg/kg per 
day for 12 days and antilarval measures. Again in 1982, the assessment committee 
recommended extension of NFCP to rural areas through primary health-care sys-
tem with 100% central assistance [5]. The fourth assessment in 1995 recommended 
to launch a project on the eradication of B. malayi, integrated vector control for all 
vector borne diseases, adoption of model bye-laws for effective control of vectors in 
domestic situation and fresh delimitation survey in rural areas.
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5.2 Diethylcarbamazine-medicated salt
Mass treatment with DEC-medicated salt at community level has been used 
in a number of places as a control measure for lymphatic filariasis. In India this 
regimen was initiated as pilot projects in 1968–1969 in Uttar Pradesh and Andhra 
Pradesh. This showed very encouraging results. A recent review from 11 com-
munities from China, India, Taiwan, Tanzania and Haiti on DEC-medicated salt 
in high-endemic districts and also in B. malayi areas opined high impact of this 
strategy which may be an end game for LF elimination. In 1976–1977 the distribu-
tion of 0.1% DEC-medicated salt was distributed in a population of 25,000 in 
Lakshadweep Island. There was an 80% reduction on Mf rate and 90% on circu-
lating Mf after 1 year. Similarly, 0.2% salt conducted in Karaikal, Puducherry, 
showed 98% reduction on Mf [13]. A recent study on DEC-fortified salt (0.2%) 
and iodine for the elimination of diurnally sub-periodic W. bancrofti in Andaman 
and Nicobar Island showed encouraging results. Community coverage of >90% 
resulted in the reduction of Mf rate from 2.27 to 0.14% in the DEC-salt-arm (<1% 
in all the villages) and 1.26 to 0.74% (>1% in 4 out of 14 villages) in the MDA-arm. 
Antigen prevalence reduced to zero from 1.0 (DEC-salt + MDA-arm) to 6.3% 
(MDA-arm) in 2–3 years old, 1.2 to 3.6% from 2.9 in the DEC-salt-arm and 4.5% 
in the MDA-arm among 6–7 years old [14]. However, studies have indicated that it 
has to be used in specific situations [15].
5.3 Improved diagnosis of lymphatic filariasis
There are several methods for the diagnosis of LF. The microfilariae can be 
detected directly through blood smear examination, membrane filtration method, 
DEC-provocative test and quantitative buffy coat methods. Other methods are 
polymerase chain reaction (PCR), ultrasonography, lymphoscintigraphy (LSG), 
X-ray diagnosis and also hematology [16].
Circulating microfilariae can be detected by examining thick smears 
(20–60 μl) of finger-prick blood. Based on the periodicity of the microfilariae, 
blood samples are collected either at night hours or during daytime (in Andaman 
Nicobar Islands where W. bancrofti is transmitted by Aedes). The method is cheap 
and feasible at individual and community levels for mapping the endemicity of 
lymphatic filariasis and monitoring of MDA activities [17]. It has been observed 
that blood smear preparation on the micro-slides is a cumbersome process. 
Alternatively though not recommended in the programme, the finger-pricked 
whole blood (50 μl) can be collected in citrate–phosphate-dextrose (CPD) 
solution charged (25 μl) in 1.5 ml microfuge tubes. The tubes can be kept in +4°C 
freezer and can be examined within 48 hours. CPD-mixed whole blood (20 μl) 
are drawn by micropipette and placed in a micro-slide. The blood is smeared on 
the micro-slide and examined under10× microscope when the blood is wet. In 
positive samples, live moving parasites can be seen easily. This is a very simple 
method and can be easily executed. If needed, the dry smears can be stained for 
future reference.
The Filariasis Test Strip (FTS) of Alere (now Abbott Diagnostics) is a rapid 
diagnostic test recommended for mapping, monitoring and transmission assess-
ment surveys (TAS) for the qualitative detection of W. bancrofti antigen in human 
blood samples. Now, the FTS has replaced the Binax Now filariasis immunochro-
matographic test (ICT), which also detects the same antigen in blood samples. 
The Brugia Rapid point-of-care cassette test (BRT) manufactured by Reszon 
Diagnostics is recommended for use during TAS to detect IgG4 antibody against 
Brugia spp. in human blood samples [17].
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5.4 Mass drug administration its coverage and impact
In India, in the initial process of ELF, a district-level survey in 2000 revealed 
that of the 289 districts, 257 were endemic for LF [18]. In 2002, the National Health 
Policy had set the interim goal for the elimination of this disease in India by the 
year 2015 [19]. To support GPELF by raising funds and helping in various other 
ways, a global coalition was forged among 43 different donors constituting the 
Global Alliance to Eliminate Lymphatic Filariasis (GAELF). One of the partners 
GlaxoSmithKline has volunteered to supply the total quantity of albendazole tablets 
required to eliminate LF globally, free of cost [20]. The DEC tablets needed for the 
programme in India is being supplied by the central government [19].
In 2004, the elimination of LF programme was launched on June 5 in 202 
districts of 15 states and 5 union territories. However, based on the experience 
of MDA in June 2004 when high temperature prevailed in most of the places, 
the date of ‘National Filaria Day’ was changed to November 11 in consultation 
with the states. To promote and create awareness on LF, this date was observed 
as ‘National Filaria Day’ since then. In the beginning, DEC was introduced under 
the MDA programme and, in 2007 ALB, was added with DEC as a global strategy. 
Gradually 255 districts were brought under MDA, and the assessment in 2013 indi-
cated that 203 districts out of 255 had reported microfilaria rate <1% [21–24]. The 
number of districts reporting Mf rate below 1% increased to 222 and in 53 districts 
where MDA was withdrawn as halt in transmission was indicated. A transmission 
assessment survey (TAS) was qualified for 68 districts. The remaining districts 
were struggling to achieve the goal, making the MDA twice in a year [25].
5.5 Transmission assessment survey
TAS is a tool designed to know whether or not transmission is interrupted by 
MDA. In case, the transmission has been interrupted; the prevalence of circulat-
ing antegenaemia among children born after initiation of MDA should be below 
critical threshold, so that the transmission of disease is no longer sustainable and 
future generation will be free from this disease. Before TAS, it should be ensured 
that all implementation units (IUs) have had at least five effective MDAs with >65% 
of population coverage and each of sentinel, spot and additional spot sites had 
achieved <1% Mf rate [26].
China and the Republic of Korea have declared to have eliminated lymphatic 
filariasis as a public health problem in 2007 and 2008, respectively. According to 
the WHO, 81 endemic countries were reduced to 72 requiring MDA. Out of the 72 
countries, 15 have been declared to have eliminated LF as a public health problem. 
These countries are Togo, Egypt, Maldives, Sri Lanka, Thailand, American Samoa, 
Cambodia, Cook Islands, Marshall Islands, Niue, Palau, Tonga, Vanuatu, Viet Nam 
and Wallis and Futuna [26].
Another six countries, namely, Malawi, Brazil, Bangladesh, Kiribati and Lao 
PDR have stopped MDA and are under post-MDA surveillance. Recent report 
indicates that two countries Kiribati and Yemen have eliminated LF [17]. Out of the 
remaining, 5 have not yet started MDA, 32 have fully scaled up MDA and 14 thought 
to be started and MDA is yet to be scaled up fully [26].
6. Discussion
Now India is on a critical phase for ELF facing serious challenges. The main 
challenge is the implementation of MDA with improved actual drug compliance so 
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as to cover >80% at-risk population. It is required to have continued IEC activities, 
community engagement and all-round support [27]. It is really a huge operational 
and logistical challenge to cover about 650 million populations for the MDA 
programme.
In June 2018, in the 10th GPELF meeting at New Delhi, India, the govern-
ment of India launched Accelerated Plan for Lymphatic Filariasis Elimination 
(APELF). A triple-drug therapy or IDA (IVM, DEC and ALB) along with com-
munity engagement has been planned for accelerating the LF elimination in 
India [28, 29]. As a pilot project, IDA has been rolled out successfully across four 
districts in India. These districts are Arwal in Bihar (20 December 2018), Simdega 
in Jharkhand (10 January 2019), Nagpur in Maharashtra (20 January 2019) and 
Varanasi in Uttar Pradesh (20 February 2019). A total of 8.07 million people out of 
10.7 million vulnerable people (75.4%) were benefitted with the IDA medicines. 
The IDA approach is to be scaled up in all endemic districts to eliminate LF by 
2021. It is expected that with triple-drug combination, if effective, actual drug 
compliance is achieved; the MDA districts may qualify for TAS and also clear the 
TAS successfully.
Another important issue is asymptomatic cases in children age group. In 
some endemic areas, about 30% of children have acquired LF by the age of 
4 years either with the presence of Mf or W. bancrofti antigen in their blood [30]. 
Similarly, in a B. malayi area in Kerala, asymptomatic Mf has been demonstrated 
in children through LSG [31]. LF parasites in human do not have animal reser-
voirs. But human dirofilariasis, i.e. zoonotic transmission to human, cannot be 
ruled out. This thing should be kept in mind after successful ELF in human [32]. 
There are other issues of management of acute and chronic filariasis cases and 
treatment of adenolymphangitis (ADL) cases with antibiotics since the major-
ity of acute episodes are bacterial origin. The APELF provides free morbidity 
management and disability prevention services through kits and corrective 
surgeries [28].
Vector surveillance is another important tool to facilitate in instituting vec-
tor control measures as well as to assess the infection in vectors in the areas. 
Xenomonitoring, in other words, the presence of Mf larvae in vector mosquitoes, 
is a method to assess the effectiveness of the post-MDA and TAS. Specific PCR 
technique is applied [33]. Recently Khatri et al. screened the presence of W. ban-
crofti L3-specific Ssp1 gene in trapped mosquitoes by PCR in certain districts in 
Maharashtra and Karnataka. This indicated that MDA needed to be strengthened 
[33]. Scaling up xenomonitoring is a big challenge in existing infrastructure 
with weak strength of skilled entomologists. At present IVM has been planned to 
introduce in all LF endemic districts in India covering many districts endemic for 
malaria also. IVM introduction in context of malaria control is towards targeting 
their vector populations [34]. It is important to assess the impact of other coexistent 
diseases in the same eco-endemic regions [35].
7. Conclusion
India is on a very strong ground to achieve lymphatic elimination [19]. Several 
efforts are now in place. The total disability-adjusted life years (DALYs) lost due 
to LF is around 2.06 million, resulting in an annual wage loss of US $811 million 
[36]. A special emphasis has been given on the general hygiene and environmental 
management of mosquito vectors under the Swachh Bharat Mission (Clean India 
Movement) and also to provide special incentive under the Ayushman Bharat to 
make the programme effective and successful [37].
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